Molecular basis of hereditary iron homeostasis defects

Hematology

Volumn 15, Issue 2, 2010, Pages 96-111

  Horvathova, Monika ^a   Ponka, Prem ^b   Divoky, Vladimir ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Hemochromatosis; Iron deficiency; Iron homeostasis

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; FERRITIN; FERROPORTIN; FURIN; GROWTH DIFFERENTIATION FACTOR 15; HEME OXYGENASE 1; HEMOJUVELIN; HEPCIDIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; IRON SULFUR PROTEIN; MATRIPTASE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 1; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SMAD1 PROTEIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR 2; UNINDEXED DRUG; UROPORPHYRINOGEN DECARBOXYLASE; UROPORPHYRINOGEN III SYNTHASE;

DRUG MEGADOSE; ERYTHROPHAGOCYTOSIS; HEMOCHROMATOSIS; HUMAN; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; IRON METABOLISM DISORDER; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; METABOLIC REGULATION; MISSENSE MUTATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL TRANSPORT; DUODENUM; ENTEROCYTES; ERYTHROID CELLS; ERYTHROPOIESIS; HEMEPROTEINS; HOMEOSTASIS; HUMANS; INTESTINAL ABSORPTION; IRON; IRON OVERLOAD; IRON, DIETARY; IRON-BINDING PROTEINS; MACROPHAGES; METAL METABOLISM, INBORN ERRORS; MICE; MICE, KNOCKOUT; NONHEME IRON PROTEINS; OXYGEN;

EID: 77952137434     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12583347009810     Document Type: Review

References (158)

1. Priwitzerova M, Pospisilova D, Prchal JT et al. Severe hypochromic microcytic anemia caused by a congenital defect of the iron transport pathway in erythroid cells. Blood 2004; 103: 3991-3992.
2. Mims MP, Guan Y, Pospisilova D et al. Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 2005; 105: 1337-1342.
3. Priwitzerova M, Nie G, Sheftel AD, Pospisilova D, Divoky V, Ponka P. Functional consequences of the human DMT1 (SLC11A2) mutation on protein expression and iron uptake. Blood 2005; 106: 3985-3987.
4. Cammack R, Wrigglesworth JH, Baum H. Iron-dependent enzymes in mammalian systems. In: Ponka P, Schulman HM, Woodworth RD. (eds) Iron transport and storage. Boca Raton, FL: CRC, 1990; 17-40.
5. Koury MJ, Ponka P. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr 2004; 24: 105-131.
6. Shayeghi M, Latunde-Dada GO, Oakhill JS et al. Identification of an intestinal heme transporter. Cell 2005; 122: 789-801.
7. Qiu A, Jansen M, Sakaris A et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006; 127: 917-928.
8. Boni RE, Huch Boni RA, Galbraith RA, Drummond GS, Kappas A. Tin-mesoporphyrin inhibits heme oxygenase activity and heme-iron absorption in the intestine. Pharmacology 1993; 47: 318-329.
9. McKie AT, Barrow D, Latunde-Dada GO et al. An ironregulated ferric reductase associated with the absorption of dietary iron. Science 2001; 291: 1755-1759.
10. Gunshin H, Starr CN, Direnzo C et al. Cybrd1 (duodenal cytochrome b) is not necessary for dietary iron absorption in mice. Blood 2005; 106: 2879-2883.
11. Fleming MD, Trenor CC III, Su MA et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997; 16: 383-386.
12. Gunshin H, Mackenzie B, Berger UV et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388: 482-488.
13. Garrick LM, Gniecko K, Hoke JE, Al-Nakeeb A, Ponka P, Garrick MD. Ferric-salicylaldehyde isonicotinoyl hydrazone, a synthetic iron chelate, alleviates defective iron utilization by reticulocytes of the Belgrade rat. J Cell Physiol 1991; 146: 460-465.
14. Gunshin H, Fujiwara Y, Custodio AO, Direnzo C, Robine S, Andrews NC. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver. J Clin Invest 2005; 115: 1258-1266.
15. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996; 1275: 161-203.
16. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275: 19906-19912.
17. Donovan A, Brownlie A, Zhou Y et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403:776-781.
18. McKie AT, Marciani P, Rolfs A et al. A novel duodenal ironregulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000; 5: 299-309.
19. Donovan A, Lima CA, Pinkus JL et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005; 1: 191-200.
20. Vulpe CD, Kuo YM, Murphy TL et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the SLA mouse. Nat Genet 1999; 21: 195-199.
21. Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 1997; 89: 1-25.
22. Trenor CC, Campagna DR, Sellers VM, Andrews NC, Fleming MD. The molecular defect in hypotransferrinemic mice. Blood 2000; 96: 1113-1118.
23. Levy JE, Jin O, Fujiwara Y, Kuo F, Andrews NC. Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat Genet 1999; 21: 396-399.
24. Ohgami RS, Campagna DR, Greer EL et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet 2005; 37: 1264-1269.
25. Shaw GC, Cope JJ, Li L et al. Mitoferrin is essential for erythroid iron assimilation. Nature 2006; 440: 96-100.
26. Ajioka RS, Phillips JD, Kushner JP. Biosynthesis of heme in mammals. Biochim Biophys Acta 2006; 1763: 723-736.
27. Paw BH, Shaw GC, Cope JJ et al. Frascati, a mitochondrial solute transporter, and its role in vertebrate erythropoiesis. Blood (ASH Annu Meet Abstr) 2004; 104: 49.
28. Zhang AS, Sheftel AD, Ponka P. Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood 2005; 105: 368-375.
29. Sheftel AD, Zhang AS, Brown C, Shirihai OS, Ponka P. Direct interorganellar transfer of iron from endosome to mitochondrion. Blood 2007; 110: 125-132.
30. White RA, Boydston LA, Brookshier TR et al. Iron metabolism mutant hbd mice have a deletion in Sec15l1, which has homology to a yeast gene for vesicle docking. Genomics 2005; 86: 668-673.
31. Lim JE, Jin O, Bennett C et al. A mutation in Sec15l1 causes anemia in hemoglobin deficit (hbd) mice. Nat Genet 2005; 37: 1270-1273.
32. Brenner DA, Didier JM, Frasier F, Christensen SR, Evans GA, Dailey HA. A molecular defect in human protoporphyria. Am J Hum Genet 1992; 50: 1203-1210.
33. Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell Biol 2009; 10: 218-227.
34. Lill R, Mühlenhoff U. Maturation of iron-sulfur proteins in eukaryotes: mechanisms, connected processes, and diseases. Annu Rev Biochem 2008; 77: 669-700.
35. Camaschella C, Campanella A, de Falco L et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 2007; 110: 1353-1358.
36. Poss KD, Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci USA 1997; 94: 10919-10924.
37. Jabado N, Canonne-Hergaux F, Gruenheid S, Picard V, Gros P. Iron transporter Nramp2/DMT-1 is associated with the membrane of phagosomes in macrophages and Sertoli cells. Blood 2002; 100: 2617-2622.
38. Soe-Lin S, Apte SS, Andriopoulos B Jr et al. Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo. Proc Natl Acad Sci USA 2009; 106: 5960-5965.
39. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA 1999; 96: 10812-10817.
40. Ganz T, Nemeth E. Regulation of iron acquisition and iron distribution in mammals. Biochim Biophys Acta 2006; 1763: 690-699.
41. Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 2008; 28: 197-213.
42. Eisenstein RS, Blemings KP. Iron regulatory proteins, iron responsive elements and iron homeostasis. J Nutr 1998; 128: 2295-2298.
43. Iwai K, Drake SK, Wehr NB et al. Iron-dependent oxidation, ubiquitination, and degradation of iron regulatory protein 2: implications for degradation of oxidized proteins. Proc Natl Acad Sci USA 1998; 95: 4924-4928.
44. Kaptain S, Downey WE, Tang C et al. A regulated RNA binding protein also possesses aconitase activity. Proc Natl Acad Sci USA 1991; 88: 10109-10113.
45. Cairo G, Pietrangelo A. Iron regulatory proteins in pathobiology. Biochem J 2000; 352: 241-250.
46. Ishikawa H, Kato M, Hori H et al. Involvement of heme regulatory motif in heme-mediated ubiquitination and degradation of IRP2. Mol Cell 2005; 19: 171-181.
47. Cooperman SS, Meyron-Holtz EG, Olivierre-Wilson H, Ghosh MC, McConnell JP, Rouault TA. Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2. Blood 2005; 106: 1084-1091.
48. Galy B, Hö lter SM, Klopstock T et al. Iron homeostasis in the brain: complete iron regulatory protein 2 deficiency without symptomatic neurodegeneration in the mouse. Nat Genet 2006; 38: 967-969.
49. LaVaute T, Smith S, Cooperman S et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 2001; 27: 209-214.
50. Meyron-Holtz EG, Ghosh MC, Iwai K et al. Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. EMBO J 2004; 23: 386-395.
51. Smith SR, Ghosh MC, Ollivierre-Wilson H, Tong WH, Rouault TA. Complete loss of iron regulatory proteins 1 and 2 prevents viability of murine zygotes beyond the blastocyst stage of embryonic development. Blood Cells Mol Dis 2006; 36: 283-287.
52. Galy B, Ferring-Appel D, Kaden S, Gröne HJ, Hentze MW. Iron regulatory proteins are essential for intestinal function and control key iron absorption molecules in the duodenum. Cell Metab 2008; 7: 79-85.
53. Sanchez M, Galy B, Muckenthale MU, Hentze MW. Iron regulatory proteins limit hypoxia-inducible factor-2a expression in iron deficiency. Nat Struct Mol Biol 2007; 14: 420-426.
54. Semenza GL. Involvement of oxygen-sensing pathways in physiological and pathological erythropoiesis. Blood 2009; 114: 2015-2019.
55. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxiainducible nuclear factors bind to an enhancer element located 39 to the human erythropoietin gene. Proc Natl Acad Sci USA 1991; 88: 5680-5684.
56. Patel SA, Simon MC. Biology of hypoxia-inducible factor 2a in development and disease. Cell Death Differ 2008; 15: 628-634.
57. Yoon D, Pastore YD, Divoky V et al. Hypoxia-inducible factor-1 deficiency results in dysregulated erythropoiesis signaling and iron homeostasis in mouse development. J Biol Chem 2006; 281: 25703-25711.
58. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. HIF-2a, but not HIF-1a, promotes iron absorption in mice. J Clin Invest 2009; 119: 1159-1166.
59. Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol 2004; 11: 251-254.
60. Levi S, Corsi B, Bosisio M et al. A human mitochondrial ferritin encoded by an intronless gene. J Biol Chem 2001; 276: 24437-24440.
61. Santambrogio P, Biasiotto G, Sanvito F, Olivieri S, Arosio P, Levi S. Mitochondrial ferritin expression in adult mouse tissues. J Histochem Cytochem 2007; 55: 1129-1137.
62. Cazzola M, Invernizzi R, Bergamaschi G et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003; 101: 1996-2000.
63. Bishop DF, Kitchen H, Wood WA. Evidence for erythroid and nonerythroid forms of delta-aminolevulinate synthase. Arch Biochem Biophys 1981; 206: 380-391.
64. Dierks P. Molecular biology of eukaryotic delta-aminolevulinate synthase. In: Dailey HA. (ed) Biosynthesis of heme and chlorophylls. New York: McGraw-Hill, 1990; 201-233.
65. Schranzhofer M, Schifrer M, Cabrera JA et al. Remodeling the regulation of iron metabolism during erythroid differentiation to ensure efficient heme biosynthesis. Blood 2006; 107: 4159-4167.
66. Welch JJ, Watts JA, Vakoc CR et al. Global regulation of erythroid gene expression by transcription factor GATA-1. Blood 2004; 104: 3136-3147.
67. Hardison R. Organization, evolution, and regulation of the globin genes. In: Steinberg MH, Forget BG, Higgs D, Nagel RL. (eds) Disorders of hemoglobin: genetics, pathophysiology and clinical management. 1st edn. Cambridge: University Press, 2001; 95-117.
68. Ney PA, Sorrentino BP, Lowrey CH, Nienhuis AW. Inducibility of the HS II enhancer depends on binding of an erythroid specific nuclear protein. Nucleic Acids Res 1990; 18: 6011-6017.
69. Chen JJ. Regulation of protein synthesis by the heme-regulated eIF2a kinase: relevance to anemias. Blood 2007; 109: 2693-2699.
70. Chefalo PJ, Oh J, Rafie-Kolpin M, Kan B, Chen JJ. Hemeregulated eIF-2a kinase purifies as a hemoprotein. Eur J Biochem 1998; 258: 820-830.
71. Rafie-Kolpin M, Chefalo PJ, Hussain Z et al. Two heme-binding domains of heme-regulated eukaryotic initiation factor-2a kinase. N terminus and kinase insertion. J Biol Chem 2000; 275: 5171-5178.
72. Uma S, Matts RL, Guo Y, White S, Chen JJ. The N-terminal region of the heme-regulated eIF2a kinase is an autonomous heme binding domain. Eur J Biochem 2000; 267: 498-506.
73. Jarman AP, Wood WG, Sharpe JA, Gourdon G, Ayyub H, Higgs DR. Characterization of the major regulatory element upstream of the human alpha-globin gene cluster. Mol Cell Biol 1991; 11: 4679-4689.
74. Sun J, Brand M, Zenke Y, Tashiro S, Groudine M, Igarashi K. Heme regulates the dynamic exchange of Bach1 and NF-E2-related factors in the Maf transcription factor network. Proc Natl Acad Sci USA 2004; 101: 1461-1466.
75. Reichard JF, Motz GT, Puga A. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res 2007; 35: 7074-7086.
76. Fukuda Y, Fujita H, Garbaczewski L, Sassa S. Regulation of beta-globin mRNA accumulation by heme in dimethyl sulfoxide (DMSO)-sensitive and DMSO-resistant murine erythroleukemia cells. Blood 1994; 83: 1662-1667.
77. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide the first report synthesized in the liver. J Biol Chem 2001; 276: 7806-7810.
78. Nicolas G, Bennoun M, Devaux I et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98: 8780-8785.
79. Viatte L, Lesbordes-Brion JC, Lou DQ et al. Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. Blood 2005; 105: 4861-4864.
80. Nicolas G, Bennoun M, Porteu A et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 2002; 99: 4596-4601.
81. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
82. Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood 2005; 106: 3979-3984.
83. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463.
84. Pigeon C, Ilyin G, Courselaud B et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-7819.
85. Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-1044.
86. Finch C. Regulators of iron balance in humans. Blood 1994; 84: 1697-1702.
87. Papanikolaou G, Tzilianos M, Christakis JI et al. Hepcidin in iron overload disorders. Blood 2005; 105: 4103-4105.
88. Tanno T, Bhanu NV, Oneal PA et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096-1101.
89. Kanda J, Mizumoto C, Kawabata H et al. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica 2008; 93: 1550-1554.
90. Tanno T, Porayette P, Sripichai O et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009; 114: 181-186.
91. Fleming RE, Ahmann JR, Migas MC et al. Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc Natl Acad Sci USA 2002; 99: 10653-10658.
92. Salter-Cid L, Brunmark A, Li Y et al. Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis. Proc Natl Acad Sci USA 1999; 96: 5434-5439.
93. Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 2005; 106: 2884-2889.
94. Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC. A mouse model of juvenile hemochromatosis. J Clin Invest 2005; 115: 2187-2191.
95. Niederkofler V, Salie R, Arber S. Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 2005; 115: 2180-2186.
96. Babitt JL, Huang FW, Wrighting DM et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006; 38: 531-539.
97. Wang RH, Li C, Xu X et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005; 2: 399-409.
98. Zhang AS, Anderson SA, Meyers KR, Hernandez C, Eisenstein RS, Enns CA. Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem 2007; 282: 12547-12556.
99. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood 2008; 111: 924-931.
100. Peyssonnaux C, Zinkernagel AS, Schuepbach RA et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117: 1926-1932.
101. Andriopoulos B Jr, Corradini E, Xia Y et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Gen 2009; 41: 482-487.
102. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Gen 2009; 41: 478-481.
103. Kautz L, Meynard D, Monnier A et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 2008; 112: 1503-1509.
104. Constante M, Jiang WL, Wang DM, Raymond VA, Bilodeau M, Santos MM. Distinct requirements for Hfe in basal and induced hepcidin levels in iron overload and inflammation. Am J Physiol Gastrointest Liver Physiol 2006; 291: G229-237
105. Kawabata H, Fleming RE, Gui D et al. Expression of hepcidin is downregulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood 2005; 105: 376-381.
106. Pietrangelo A, Caleffi A, Henrion J et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005; 128: 470-479.
107. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, Enns CA. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009; 9: 217-227.
108. Johnson MB, Enns CA. Diferric transferrin regulates transferrin receptor 2 protein stability. Blood 2004; 104: 4287-4293.
109. Robb A, Wessling-Resnick M. Regulation of transferrin receptor 2 protein levels by transferrin. Blood 2004; 104: 4294-4299.
110. Johnson MB, Chen J, Murchison N, Green FA, Enns CA. Transferrin receptor 2: evidence for ligand-induced stabilization and redirection to a recycling pathway. Mol Biol Cell 2007; 18: 743-754.
111. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab 2008; 7: 205-214.
112. Chen J, Chloupkova M, Gao J, Chapman-Arvedson TL, Enns CA. HFE modulates transferrin receptor 2 levels in hepatoma cells via interactions that differ from transferrin receptor 1/HFE interactions. J Biol Chem 2007; 282: 36862-36870.
113. Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Pathol Mech Dis 2009; 4: 489-515.
114. Corradini E, Garuti C, Montosi G et al. Bone morphogenetic protein signaling is impaired in an Hfe knockout mouse model of hemochromatosis. Gastroenterology 2009; 137: 1489-1497.
115. Du X, She E, Gelbart T et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008; 320: 1088-1092.
116. Silvestri L, Pagani A, Nai A, de Domenico I, Kaplan J, Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008; 8: 502-511.
117. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276.
118. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006; 108: 3204-3209.
119. Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr Blood Cancer 2006; 46: 554-557.
120. Lee PL, Peng H, Gelbart T, Beutler E. The IL-6-and lipopolysaccharide- induced transcription of hepcidin in HFE, transferrin receptor-2, and b2 microglobulin deficient hepatocytes. Proc Natl Acad Sci USA 2004; 101: 9263-9265.
121. Frazer DM, Wilkins SJ, Millard KN et al. Increased hepcidin expression and hypoferritaemia associated with an acute phase response are not affected by inactivation of HFE. Br J Haematol 2004; 126: 434-436.
122. Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
123. Pietrangelo A. Hereditary hemochromatosis -a new look at an old disease. N Engl J Med 2004; 350: 2383-2397.
124. Papanikolaou G, Samuels ME, Ludwig EH et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36: 77-82.
125. Roetto A, Papanikolaou G, Politou M et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33: 21-22.
126. Camaschella C, Roetto A, Cali A et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14-15.
127. Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Pathophysiology of hereditary hemochromatosis. Semin Liver Dis 2005; 25: 411-419.
128. Waheed A, Parkkila S, Zhou XY et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with b2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 1997; 94: 12384-12389.
129. Piperno A, Roetto A, Mariani R et al. Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. Haematologica 2004; 89: 359-360.
130. Montosi G, Donovan A, Totaro A et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108: 619-623.
131. Wallace DF, Pedersen P, Dixon JL et al. Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood 2002; 100: 692-694.
132. Schimanski LM, Drakesmith H, Merryweather-Clarke AT et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood 2005; 105: 4096-4102.
133. De Domenico I, Ward DM, Nemeth E et al. The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci USA 2005; 102: 8955-8960.
134. Drakesmith H, Schimanski LM, Ormerod E et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 2005; 106: 1092-1097. (Pubitemid 41076459)
135. Devalia V, Carter K, Walker AP et al. Autosomal dominant reticulo-endothelial iron overload associated with a three base pair deletion in the ferroportin 1 gene (SLC11A3). Blood 2002; 100: 695-697.
136. Cazzola M, Cremonesi L, Papaioannou M et al. Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Br J Haematol 2002; 119: 539-546.
137. Ponka P. Rare causes of hereditary iron overload. Semin Hematol 2002; 39: 249-262.
138. Beutler E, Gelbart T, Lee P, Trevino R, Fernandez MA, Fairbanks VF. Molecular characterization of a case of atransferrinemia. Blood 2000; 96: 4071-4074.
139. Trenor CC III, Campagna DR, Sellers VM, Andrews NC, Fleming MD. The molecular defect in hypotransferrinemic mice. Blood 2000; 96: 1113-1118.
140. Xu X, Pin S, Gathinji M, Fuchs R, Harris ZL. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Ann N Y Acad Sci 2004; 1012: 299-305.
141. Iolascon A, d'Apolito M, Servedio V, Cimmino F, Piga A, Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood 2006; 107: 349-354.
142. Beaumont C, Delaunay J, Hetet G, Grandchamp B, de Montalembert M, Tchernia G. Two new human DMT1 gene mutations in a patient with microcytic anemia, low ferritinemia, and liver iron overload. Blood 2006; 107: 4168-4170.
143. Ponka P, Schulman HM. Acquisition of iron from transferrin regulates reticulocyte heme synthesis. J Biol Chem 1985; 260: 14717-14721.
144. Priwitzerova M, Pospisilova D, Prchal JT et al. The first human mutation of DMT1 (Nramp2) causes severe defect of erythropoiesis that can be rescued in vitro by Fe-SIH. Blood 2003; 102(Suppl. 1): 562.
145. Pospisilova D, Mims MP, Nemeth E, Ganz T, Prchal JT. DMT1 mutation: Response of anemia to darbepoetin administration, implications for iron homeostasis. Blood 2006; 108: 404-405.
146. Iolascon A, Camaschella C, Pospisilova D, Piscopo C, Tchernia G, Beaumont C. Natural history of recessive inheritance of DMT1 mutations. J Pediatr 2008; 152: 136-139.
147. Iolascon A, De Falco L, Beaumont C. Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis. Haematologica 2009; 94: 395-408.
148. Blanco E, Kannengiesser C, Grandchamp B, Tasso M, Beaumont C. Not all DMT1 mutations lead to iron overload. Blood Cells Mol Dis 2009; 43: 199-201.
149. Finberg KE, Heeney MM, Campagna DR et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008; 40: 569-571.
150. Bessis MC, Jensen WN. Sideroblastic anaemia, mitochondria and erythroblastic iron. Br J Haematol 1965; 11: 49-51.
151. Camaschella C. Recent advances in the understanding of inherited sideroblastic anaemia. Br J Haematol 2008; 143: 27-38.
152. Cox TC, Bottomley SS, Wiley JS, Bawden MJ, Matthews CS, May BK. X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase. N Engl J Med 1994; 330: 675-679.
153. Fleming MD. The genetics of inherited sideroblastic anemias. Semin Hematol 2002; 39: 270-281.
154. Cazzola M, May A, Bergamaschi G, Cerani P, Rosti V, Bishop DF. Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood 2000; 96: 4363-4365.
155. Bekri S, May A, Cotter PD et al. A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia. Blood 2003; 102: 698-704.
156. Bottomley SS. Congenital sideroblastic anemias. Curr Hematol Rep 2006; 5: 41-49.
157. Whatley SD, Ducamp S, Gouya L et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008; 83: 408-414.
158. Guernsey DL, Jiang H, Campagna DR et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Gen 2009; 41: 651-653